Literature DB >> 31686588

Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients.

Vincent Gagné1, Anne Aubry-Morin1, Maria Plesa1,2, Rachid Abaji1,2, Kateryna Petrykey1,2, Pascal St-Onge1, Patrick Beaulieu1, Caroline Laverdière1,3, Nathalie Alos1,3, Jean-Marie Leclerc1,3, Stephen E Sallan4,5, Donna Neuberg6, Jeffery L Kutok7, Lewis B Silverman4,5, Daniel Sinnett1,3, Maja Krajinovic1,3,2.   

Abstract

Aim: To evaluate top-ranking genes identified through genome-wide association studies for an association with corticosteroid-related osteonecrosis in children with acute lymphoblastic leukemia (ALL) who received Dana-Farber Cancer Institute treatment protocols. Patients & methods: Lead SNPs from these studies, as well as other variants in the same genes, pooled from whole exome sequencing data, were analyzed for an association with osteonecrosis in childhood ALL patients from Quebec cohort. Top-ranking variants were verified in the replication patient group.
Results: The analyses of variants in the ACP1-SH3YL1 locus derived from whole exome sequencing data showed an association of several correlated SNPs (rs11553746, rs2290911, rs7595075, rs2306060 and rs79716074). The rs79716074 defines *B haplotype of the APC1 gene, which is well known for its functional role.
Conclusion: This study confirms implication of the ACP1 gene in the treatment-related osteonecrosis in childhood ALL and identifies novel, potentially causal variant of this complication.

Entities:  

Keywords:  Dana–Farber Cancer Institute cohort; Quebec childhood acute lymploblastic leukemia cohort; acute lymphoblastic leukemia; cosrticosteroids; dexamethasone; osteonecrosis; prednisone; single nucleotide polymorphism

Mesh:

Substances:

Year:  2019        PMID: 31686588      PMCID: PMC7026765          DOI: 10.2217/pgs-2019-0087

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  34 in total

1.  Association of the acid phosphatase (ACP1) gene with triglyceride levels in obese women.

Authors:  Nunzio Bottini; James MacMurray; Warren Peters; Masoud Rostamkhani; David E Comings
Journal:  Mol Genet Metab       Date:  2002-11       Impact factor: 4.797

2.  Human 18 kDa phosphotyrosine protein phosphatase (ACP1) polymorphism: studies of rare variants provide evidence that substitutions within or near alternatively spliced exons affect splicing result.

Authors:  L Rudbeck; J Dissing; K D Lazaruk; G Sensabaugh
Journal:  Ann Hum Genet       Date:  2000-03       Impact factor: 1.670

3.  A study of acid phosphatase locus 1 in women with high fat content and normal body mass index.

Authors:  Antonino De Lorenzo; Laura Di Renzo; Alberto Puja; Patrizia Saccucci; Fulvia Gloria-Bottini; Egidio Bottini
Journal:  Metabolism       Date:  2009-03       Impact factor: 8.694

4.  Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.

Authors:  Seth E Karol; Leonard A Mattano; Wenjian Yang; Kelly W Maloney; Colton Smith; ChengCheng Liu; Laura B Ramsey; Christian A Fernandez; Tamara Y Chang; Geoffrey Neale; Cheng Cheng; Elaine Mardis; Robert Fulton; Paul Scheet; F Anthony San Lucas; Eric C Larsen; Mignon L Loh; Elizabeth A Raetz; Stephen P Hunger; Meenakshi Devidas; Mary V Relling
Journal:  Blood       Date:  2015-11-20       Impact factor: 22.113

5.  Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin.

Authors:  Asim F Belgaumi; Mohammed Al-Bakrah; Mohammed Al-Mahr; Abdullah Al-Jefri; AbdulRahman Al-Musa; Mahasen Saleh; Mohammed F Salim; Mohammed Osman; Layla Osman; Hassan El-Solh
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

6.  High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Riitta A Niinimäki; Arja H Harila-Saari; Airi E Jartti; Raija M Seuri; Pekka V Riikonen; Eija L Pääkkö; Merja I Möttönen; Marjatta Lanning
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

7.  A possible mechanism of low molecular weight protein tyrosine phosphatase (LMW-PTP) activity modulation by glutathione action during human osteoblast differentiation.

Authors:  Tatiana Salles de Souza Malaspina; Willian Fernando Zambuzzi; Célio Xavier dos Santos; Ana Paula Campanelli; Francisco Rafael Martins Laurindo; Mari Cleide Sogayar; José Mauro Granjeiro
Journal:  Arch Oral Biol       Date:  2009-05-02       Impact factor: 2.633

8.  Association of acid phosphatase locus 1*C allele with the risk of cardiovascular events in rheumatoid arthritis patients.

Authors:  María Teruel; Jose-Ezequiel Martin; Carlos González-Juanatey; Raquel López-Mejias; Jose A Miranda-Filloy; Ricardo Blanco; Alejandro Balsa; Dora Pascual-Salcedo; Luis Rodriguez-Rodriguez; Benjamin Fernández-Gutierrez; Ana M Ortiz; Isidoro González-Alvaro; Carmen Gómez-Vaquero; Nunzio Bottini; Javier Llorca; Miguel A González-Gay; Javier Martin
Journal:  Arthritis Res Ther       Date:  2011-07-18       Impact factor: 5.156

Review 9.  Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action.

Authors:  Mohammad Amin Kerachian; Chantal Séguin; Edward J Harvey
Journal:  J Steroid Biochem Mol Biol       Date:  2009-02-21       Impact factor: 4.292

10.  Glucocorticoid-induced avascular bone necrosis: diagnosis and management.

Authors:  K L Chan; C C Mok
Journal:  Open Orthop J       Date:  2012-10-05
View more
  2 in total

Review 1.  Pharmacogenomics and ALL treatment: How to optimize therapy.

Authors:  Seth E Karol; Jun J Yang
Journal:  Semin Hematol       Date:  2020-10-20       Impact factor: 3.851

2.  Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations.

Authors:  Wenjian Yang; Meenakshi Devidas; Yiwei Liu; Colton Smith; Yunfeng Dai; Naomi Winick; Stephen P Hunger; Mignon L Loh; Elizabeth A Raetz; Eric C Larsen; William L Carroll; Stuart S Winter; Kimberly P Dunsmore; Leonard A Mattano; Mary V Relling; Seth E Karol
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.